Abstract:Background: Muscle aging is associated with a consistent decrease in the ability of muscle tissue to regenerate following intrinsic muscle degradation, injury or overuse. Age-related imbalance of protein synthesis and degradation, mainly regulated by AKT/mTOR pathway, leads to progressive loss of muscle mass. Maintenance of anabolic and regenerative capacities of skeletal muscles may be regarded as a therapeutic option for sarcopenia and other muscle wasting diseases. Our previous studies have demonstrated that BIO101, a pharmaceutical grade 20-hydroxyecdysone, increases protein synthesis through the activation of MAS receptor involved in the protective arm of renin-angiotensin-aldosterone system. The purpose of the present study was to assess the anabolic and pro-differentiating properties of BIO101 on C2C12 muscle cells in vitro and to investigate its effects on adult and old mice models in vivo. Methods: The effects of BIO101 on C2C12 differentiation were assessed using myogenic transcription factors and protein expression of major kinases of AKT/mTOR pathway by Western blot. The in vivo effects of BIO101 have been investigated in BIO101 orally-treated (50 mg/kg/day) adult mice (3 months) for 28 days. To demonstrate potential beneficial effect of BIO101 treatment in a sarcopenic mouse model, we use orally treated 22-month-old C57Bl6/J mice, for 14 weeks with vehicle or BIO101. Mice body and muscle weight were recorded. Physical performances were assessed using running capacity and muscle contractility tests. Results: Anabolic properties of BIO101 were confirmed by the rapid activation of AKT/mTOR, leading to an increase of C2C12 myotubes diameters (+26%, P < 0.001). Pro-differentiating effects of BIO101 on C2C12 myoblasts were revealed by increased expression of muscle-specific differentiation transcription factors (MyoD, myogenin), resulting in increased fusion index and number of nuclei per myotube (+39% and +53%, respectively, at day 6). These effects of BIO101 were like those of angiotensin (1-7) and were abolished with the use of A779, a MAS receptor specific antagonist. Chronic BIO101 oral treatment induced AKT/mTOR activation and anabolic effects accompanied with improved physical performances in adult and old animals (maximal running distance and maximal running velocity). Conclusions: Our data suggest beneficial anabolic and pro-differentiating effects of BIO101 rendering BIO101 a potent drug candidate for treating sarcopenia and possibly other muscle wasting disorders.

Alverine citrate promotes myogenic differentiation and ameliorates muscle atrophy

Acetyl genistin modulates myotube differentiation and attenuates dexamethasone-induced muscle atrophy through the FoxO1/3 signaling pathway in C2C12 myotubes

Synergistically Acting on Myostatin and Agrin Pathways Increases Neuromuscular Junction Stability and Endurance in Old Mice

Unacylated Ghrelin Protects Against Age‐Related Loss of Muscle Mass and Contractile Dysfunction in Skeletal Muscle

Protein therapy of skeletal muscle atrophy and mechanism by angiogenic factor AGGF1

Protective Effects of Cervus elaphus and Eucommia ulmoides Mixture (KGC01CE) on Muscle Loss and Function in Aged Rats

GW8510 Alleviated Muscle Atrophy and Skeletal Muscle Dysfunction in Mice Through AMPK/PGC1α Signaling

The Combination of Lactoferrin and Creatine Ameliorates Muscle Decay in a Sarcopenia Murine Model

BIO101 stimulates myoblast differentiation and improves muscle function in adult and old mice

Endomysium-permeable muscle extracellular matrix composite hydrogel for promoting functional muscle recovery in muscle atrophy

New Function of the Myostatin/activin Type I Receptor (ALK4) As a Mediator of Muscle Atrophy and Muscle Regeneration

Challenging Sarcopenia: Exploring AdipoRon in Aging Skeletal Muscle as a Healthspan-Extending Shield

Identification of a KLF5-dependent program and drug development for skeletal muscle atrophy

Durable Muscle Extracellular Matrix Engineered with Adhesive Phenolic Moieties for Effective Skeletal Muscle Regeneration in Muscle Atrophy

Restorative effects of (+)-epicatechin in a rodent model of aging induced muscle atrophy: underlying mechanisms

An inhibitor of transforming growth factor beta type I receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy

MPS 07-06 5-AMINOLEVULINIC ACID, A MATERIAL FOR MITOCHONDRIAL ELECTRON CARRIER, IMPROVES EXERCISE ENDURANCE THROUGH BOTH MUSCLE ENHANCEMENT AND ACTIVATION OF MUSCLE MITOCHONDRIA IN SARCOPENIC MICE.

Cyclo His‐Pro Attenuates Muscle Degeneration in Murine Myopathy Models

Follistatin-induced muscle hypertrophy in aged mice improves neuromuscular junction innervation and function

Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy

Myogenesis Effects of RGX365 to Improve Skeletal Muscle Atrophy